News headlines about Gilead Sciences (NASDAQ:GILD) have been trending somewhat positive on Friday, according to AlphaOne Sentiment Analysis. The research firm, a division of Accern, scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Gilead Sciences earned a news sentiment score of 0.24 on AlphaOne’s scale. AlphaOne also gave news stories about the biopharmaceutical company an impact score of 90 out of 100, meaning that recent news coverage is very likely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have impacted AlphaOne Sentiment’s rankings:

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences (NASDAQ:GILD) traded down 1.06% during trading on Friday, reaching $64.12. 55,401 shares of the company’s stock traded hands. The stock has a 50-day moving average of $65.77 and a 200-day moving average of $69.26. The company has a market capitalization of $83.79 billion, a price-to-earnings ratio of 6.78 and a beta of 1.20. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $88.85.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 EPS for the quarter, beating the Zacks’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. On average, equities analysts predict that Gilead Sciences will post $8.20 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be given a $0.52 dividend. The ex-dividend date of this dividend is Wednesday, June 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.24%. Gilead Sciences’s payout ratio is currently 21.99%.

GILD has been the topic of a number of research reports. Barclays PLC restated a “buy” rating and issued a $90.00 price target on shares of Gilead Sciences in a research note on Wednesday, March 22nd. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $76.20 target price on the stock. in a research report on Wednesday, March 15th. Jefferies Group LLC reiterated a “buy” rating and set a $63.00 target price on shares of Gilead Sciences in a research report on Wednesday, March 15th. Mizuho lowered their price objective on Gilead Sciences from $88.00 to $77.00 and set a “buy” rating on the stock in a research report on Wednesday, March 1st. Finally, Credit Suisse Group restated a “buy” rating and issued a $79.00 price objective on shares of Gilead Sciences in a research report on Wednesday, March 1st. Twelve investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $80.61.

TRADEMARK VIOLATION WARNING: “Gilead Sciences (GILD) Earning Somewhat Positive Press Coverage, Analysis Shows” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/06/16/gilead-sciences-gild-receives-daily-coverage-optimism-rating-of-0-24-updated-updated.html.

In related news, Director John Francis Cogan sold 9,943 shares of Gilead Sciences stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total value of $668,666.75. Following the sale, the director now directly owns 47,562 shares in the company, valued at approximately $3,198,544.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at $214,973,917.42. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,276 shares of company stock worth $5,932,578. Insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.